These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10197384)

  • 1. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy.
    Barreiro PM; Dona MC; Castilla J; Soriano V
    AIDS; 1999 Mar; 13(4):525-6. PubMed ID: 10197384
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
    Fätkenheuer G; Römer K; Kamps R; Salzberger B; Burger D
    AIDS; 2001 Nov; 15(17):2334-5. PubMed ID: 11698713
    [No Abstract]   [Full Text] [Related]  

  • 4. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 5. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
    Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
    AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
    [No Abstract]   [Full Text] [Related]  

  • 6. Using databases for clinical outcomes.
    Clay PG
    AIDS; 2002 Jan; 16(2):300-3. PubMed ID: 11807321
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses.
    Maggiolo F; Callegaro A; Gregis G; Quinzan G; Ripamonti D; Arici C; Goglio A; Suter F
    AIDS; 2002 Jan; 16(2):298-9. PubMed ID: 11807319
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduction of HIV-associated oral lesions after highly active antiretroviral therapy.
    Aguirre JM; Echebarria MA; Ocina E; Ribacoba L; Montejo M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Aug; 88(2):114-5. PubMed ID: 10468448
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
    Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
    AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients.
    Revankar SG; Sanche SE; Dib OP; Caceres M; Patterson TF
    AIDS; 1998 Dec; 12(18):2511-3. PubMed ID: 9875598
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
    De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Zaccarelli M; Tozzi V; Ammassari A; Murri R; Antinori A
    AIDS; 2000 Jul; 14(11):1655-6. PubMed ID: 10983653
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the benefits of antiretroviral therapy.
    Gulick RM
    Ann Intern Med; 2000 Sep; 133(6):471-3. PubMed ID: 10975966
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC
    AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency and durability of antiretroviral therapy.
    Daar ES
    J Acquir Immune Defic Syndr; 2003 Oct; 34 Suppl 2():S111-7. PubMed ID: 14703939
    [No Abstract]   [Full Text] [Related]  

  • 16. The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
    Reijers MH; Weverling GJ; Jurriaans S; Roos MT; Wit FW; Weigel HM; Ten Kate RW; Mulder JW; Richter C; Ter Hofstede HJ; Sprenger H; Hoetelmans RM; Schuitemaker H; Lange JM
    AIDS; 2001 Jan; 15(1):129-31. PubMed ID: 11192858
    [No Abstract]   [Full Text] [Related]  

  • 17. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Côte d'Ivoire.
    Borget MY; Diallo K; Adje-Toure C; Chorba T; Nkengasong JN
    J Clin Virol; 2009 May; 45(1):72-5. PubMed ID: 19375979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD7-lymphocyte subset is expanded in HIV-infected patients with low CD4 cell count rescue during highly active antiretroviral therapy.
    Meroni L; Varchetta S; Manganaro D; Moscatelli G; Moroni M; Galli M
    AIDS; 1999 Apr; 13(5):621-2. PubMed ID: 10203388
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
    Clark NM; Dieng Sarr A; Sankalé JL; Kanki PJ; Kazanjian P; Winfield R; Markovitz DM
    AIDS; 1998 Dec; 12(18):2506-7. PubMed ID: 9875594
    [No Abstract]   [Full Text] [Related]  

  • 20. Protease inhibitor-sparing regimens: new evidence strengthens position.
    Moyle GJ
    J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S17-25; quiz S26-8. PubMed ID: 12946062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.